The serological prevalence of anti tTG-IgA for CD was 4.14% (95% CI: 2.02-8.31) in men with IBS and 4.16% (95% CI: 1.79-9.39) in women with IBS. This evidence concerns the gene CD79A and irritable bowel syndrome.